Gilead Sciences stock after-hours at EUR 133.47: plus 0.12 percent versus Lang & Schwarz prior close
Published on 09/29/2026 at 20:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences was at EUR 133.47 after-hours at 8:20 p.m. CEST on September 29, 2026, up 0.12 percent versus the Lang & Schwarz prior close of EUR 133.31.
Trading day in focus
The Lang & Schwarz quote showed a bid of EUR 133.38 and an ask of EUR 133.56. The price data is separate from Gilead's corporate announcements.
Lenacapavir access planning
On September 16, Gilead Sciences, Inc. said it had expanded six royalty-free voluntary licensing agreements to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis. The agreements cover 120 high-incidence countries and are intended to support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial continues, according to a Gilead release.
Gilead said on September 15 that it had agreed with the Pan American Health Organization to create a regional pathway for access to twice-yearly lenacapavir for HIV prevention across all PAHO Member States in Latin America and the Caribbean. The agreement uses PAHO's Regional Revolving Funds to support country-led adoption and implementation, according to the company's investor-relations release.
